Proprietary TechnologyNanexa's proprietary NEX-20 platform offers a competitive advantage in drug delivery, potentially enhancing efficacy and safety, which can attract partnerships and drive long-term growth.

Low LeverageA low debt-to-equity ratio suggests financial stability and reduced risk, providing the company with flexibility to invest in growth opportunities without significant financial strain.

Partnership Revenue ModelNanexa's revenue model, based on partnerships and collaborations, allows for diversified income streams and potential for steady cash flow from licensing and royalties.

Bears Say

Negative Cash FlowPersistent negative cash flow indicates ongoing cash burn, which can limit the company's ability to invest in growth and may necessitate additional financing, impacting long-term sustainability.

Revenue ContractionSignificant revenue contraction highlights challenges in market penetration and product adoption, which could hinder long-term growth prospects and profitability.

Negative ProfitabilityOngoing operational losses and negative profitability metrics reflect challenges in achieving sustainable growth and may impact the company's ability to attract investment and finance operations.

Nanexa AB News

Nanexa AB’s Phase 1 Study on NEX-22A: A Potential Game-Changer for Diabetes Treatment?

Nanexa AB (($DE:40M)) announced an update on their ongoing clinical study. Study Overview: The recent clinical study by...

5M ago

40M

NANEXA FAQ

What was Nanexa AB’s price range in the past 12 months?

Nanexa AB lowest stock price was kr0.70 and its highest was kr5.00 in the past 12 months.

What is Nanexa AB’s market cap?

Nanexa AB’s market cap is kr571.23M.

When is Nanexa AB’s upcoming earnings report date?

Nanexa AB’s upcoming earnings report date is Apr 29, 2026 which is in 65 days.

How were Nanexa AB’s earnings last quarter?

Nanexa AB released its earnings results on Feb 19, 2026. The company reported kr0.101 earnings per share for the quarter, beating the consensus estimate of N/A by kr0.101.

Is Nanexa AB overvalued?

According to Wall Street analysts Nanexa AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Nanexa AB pay dividends?

Nanexa AB does not currently pay dividends.

What is Nanexa AB’s EPS estimate?

Nanexa AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nanexa AB have?

Nanexa AB has 158,676,150 shares outstanding.

What happened to Nanexa AB’s price movement after its last earnings report?

Nanexa AB reported an EPS of kr0.101 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.75%.

Which hedge fund is a major shareholder of Nanexa AB?

Currently, no hedge funds are holding shares in SE:NANEXA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nanexa AB

Nanexa AB (NANEXA) is a biotechnology company specializing in drug delivery systems, particularly in the development of its proprietary platform, NEX-20, designed to enhance the efficacy and safety of therapeutic compounds. The company operates primarily in the pharmaceutical sector, focusing on the formulation and delivery of biopharmaceuticals to improve patient outcomes. Nanexa's core products include advanced drug formulations that utilize its unique technology to optimize the release profiles of active pharmaceutical ingredients.